Literature DB >> 21883457

The transseptal approach to the mitral valve during multivalvular surgery.

Koray Aykut1, Bulent Celik, Unal Acıkel.   

Abstract

AIM: We investigated the short and mid-term outcome of the transseptal approach to the mitral valve during multivalvular surgery.
METHODS: Within a three-year period ending in May 2010, we used the transseptal approach in performing mitral valve surgery in 62 patients. Procedures performed were: mitral valve replacement and tricuspid annuloplasty in 40 patients, both aortic and mitral valve replacement with tricuspid annuloplasty in 13 patients, mitral valve and tricuspid valve replacement in eight patients and mitral valve repair and tricuspid annuloplasty in addition to coronary artery bypass surgery in one patient.
RESULTS: There were no complications associated with the transseptal approach. There were no conduction abnormalities, nor were there any procedure-related deaths.
CONCLUSION: We conclude that use of the transseptal approach for mitral valve operations is simple and safe in patients necessitating right atriotomy for concomitant procedures.
© 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21883457     DOI: 10.1111/j.1540-8191.2011.01294.x

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


  2 in total

1.  Transseptal Approach versus Left Atrial Approach to Mitral Valve: A Propensity Score Matching Study.

Authors:  Omid Rezahosseini; Mohamadreza Rezaei; Seyed Hossein Ahmadi Tafti; Arash Jalali; Payvand Bina; Atefeh Ghiasi; Abbasali Karimi; Kiomars Abbasi; Mahmood Shirzad; Saeed Davoodi; Abbas Salehi Omran
Journal:  J Tehran Heart Cent       Date:  2015-10-27

2.  Mitral commissurotomy through the left ventricle apical orifice with Heart Ware left ventricular assist device implantation.

Authors:  Prashant Nanasaheb Mohite; Bartlomiej Zych; Aron Frederik Popov; Nikhil Patil; Suvitesh Luthra; Mike Hedger; Andre Ruediger Simon; Mohammed Amrani
Journal:  J Cardiothorac Surg       Date:  2013-06-08       Impact factor: 1.637

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.